ClinicalTrials.gg
CompletedNCT07452692Updated Nov 3, 2026

A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects

A Phase 1 interventional study of Selegiline Transdermal Delivery System in Major Depressive Disorder (MDD), sponsored by Corium Innovations, Inc.. Completed at 3 sites in Bulgaria. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Corium Innovations, Inc. (formerly part of Corium, Inc.) · Phase 1, Interventional, and Other

Updated Nov 3, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Depressive Disorder, Major with a site in Bulgaria — 10 open to participants now, 10 under way, 6 of them phase 3. Depressive Disorder, Major · Bulgaria.

Enrollment
47th of 59
232 · median 470
Started
2026
with 1 other
Phase 1
Only one
of the 60
Registered
59th of 60
by date

Among the 60 studies in Depressive Disorder, Major with a site in Bulgaria, this one is the 47th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1, and was the 59th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 60 studies in Depressive Disorder, Major with a site in Bulgaria are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Depressive Disorder, Major with a site in Bulgaria, or all of them as a file.
02

Study summary

The two products used in this study are transdermal patches that contain selegiline. The test drug is the Selegiline Transdermal Delivery System (TDS). The comparator drug is the EMSAM® TDS.

The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products.

The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.

Read the detailed description

This is a multi-center, evaluator-blinded, randomized phase 1 study evaluating skin irritation and skin sensitization of Selegiline transdermal system in comparison to EMSAM® transdermal patch in healthy volunteers. The study will consist of a 4-week Screening Phase and a Treatment Phase. The Treatment Phase will consist of the following periods: an Induction Period, a Rest Period followed by a Challenge Period and if needed, a Re-Challenge Period.

Trained study staff will examine the patch application sites at scheduled time points and will score any skin reactions using standardized assessment scales. In addition, photographs of the patch application site will be taken to document adhesion status while the patch is being worn.

Furthermore, the overall safety of the test product will be compared with that of the comparator product by monitoring and recording any adverse events, side effects, or discomfort experienced during the study.

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female non-smoking subject.
  • Lack of abnormalities in health assessments performed at screening as deemed by the Investigator (or designee)
  • within the range (including the borders) of 18.5 to 29.9 kg/m2

Exclusion criteria

Exclusion criteria:

  • Medical history or presence of ANY current dermatological condition such as atopy, psoriasis, eczema, chronic or atopic dermatitis, vitiligo, or urticaria which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study
  • Medical history or current evidence, as determined by the Investigator, of chronic infectious disease, system disorders, seizure disorders, or cardiovascular disorders (especially hypertension or family history of sudden cardiac death)
  • Medical history of a condition that would significantly influence the immune response (e.g., primary or acquired immunodeficiencies such as or AIDS; allergic diseases such as anaphylaxis, asthma, or generalized drug reaction; neoplasms such as lymphoma or leukemia; rheumatoid arthritis; or systemic lupus erythematosus)
  • illness within 4 weeks before screening visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
232 participants (actual)

Study arms

  • Other
    1/2 Selegiline TDS on left arm, 1/2 EMSAM® TDS on right arm

    Drug: Selegiline Transdermal Delivery System

  • Other
    1/2 Selegiline TDS on right arm, 1/2 EMSAM® TDS on left arm

    Drug: Selegiline Transdermal Delivery System

Interventions

  • DrugSelegiline Transdermal Delivery System

    1/2 Selegiline TDS patch 6 mg/24 hours and 1/2 EMSAM® patch 6 mg/24 hours will be administered simultaneously

06

What researchers measure

Primary outcomes

  1. Assessment of irritation

    Mean Irritation Score (MIS)

    Time frame: From enrollment through the induction, challenge and potential rechallenge phases, up to 15 weeks.

  2. Assessment of sensitization

    Number and proportion of subjects sensitized and potentially sensitized to each TDS unit

    Time frame: From enrollment through induction, challenge and potential re-challenge phase, up to 15 weeks.

07

Study locations

3 sites
  • MHAT Skin Systems EOOD
    Elin Pelin, 2100, Bulgaria
  • Diagnostic & Consultative Center "Ascendent" Ltd.
    Sofia, 1202, Bulgaria
  • Medical Center Neovitro
    Sofia, 1404, Bulgaria
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2026 to primary completion in Sep 2026, 1 month.

Of 40 industry-sponsored phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 12. This study's 1 month is below that.

Counting every sponsor, half of 88 studies reached it within 16 months; a quarter within 5 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 5, 2026
StartActual
Aug 23, 2026
Primary completionActual
Sep 26, 2026was Oct 2026
CompletionActual
Sep 26, 2026was Oct 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 3, 2026
Primary completion
Oct 6, 2026→Sep 26, 2026 (actual)
Nov 3, 2026
Study completion
Oct 13, 2026→Sep 26, 2026 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Completed
    Primary completion Oct 6, 2026→Sep 26, 2026 (now actual)
    Study completion Oct 13, 2026→Sep 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07452692
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Aug 23, 2026
Primary completion
Sep 26, 2026
Completion
Sep 26, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion